Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Accumulated Expenses (2016 - 2019)

Historic Accumulated Expenses for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $1.7 million.

  • Soleno Therapeutics' Accumulated Expenses rose 4908.93% to $1.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $1.7 million, marking a year-over-year increase of 4908.93%. This contributed to the annual value of $274000.0 for FY2018, which is 7183.97% down from last year.
  • Latest data reveals that Soleno Therapeutics reported Accumulated Expenses of $1.7 million as of Q3 2019, which was up 4908.93% from $1.1 million recorded in Q2 2019.
  • In the past 5 years, Soleno Therapeutics' Accumulated Expenses ranged from a high of $1.7 million in Q3 2019 and a low of $274000.0 during Q4 2018
  • Over the past 5 years, Soleno Therapeutics' median Accumulated Expenses value was $992000.0 (recorded in 2019), while the average stood at $1.0 million.
  • As far as peak fluctuations go, Soleno Therapeutics' Accumulated Expenses surged by 71043.55% in 2015, and later crashed by 7183.97% in 2018.
  • Quarter analysis of 5 years shows Soleno Therapeutics' Accumulated Expenses stood at $1.6 million in 2015, then plummeted by 35.66% to $1.1 million in 2016, then dropped by 7.37% to $973000.0 in 2017, then tumbled by 71.84% to $274000.0 in 2018, then skyrocketed by 527.37% to $1.7 million in 2019.
  • Its Accumulated Expenses was $1.7 million in Q3 2019, compared to $1.1 million in Q2 2019 and $992000.0 in Q1 2019.